{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T11:03:06Z","timestamp":1782903786330,"version":"3.54.5"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"Supplement_8","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In recent years, controlled human infection models (CHIMs) have become available for a range of infectious agents and have proved invaluable for understanding the disease process, pathogenesis, and mechanisms of immunity. CHIM studies have also contributed significantly to advancing development of a number of vaccines by providing an indication of vaccine efficacy. The Shigella CHIM has been established in 3 sites in the United States, and it is likely that the CHIM will play an important regulatory role for advancing the range of Shigella vaccine candidates that are currently in development. This supplement describes the harmonization of best practices across sites, with a view to maximizing the contribution that CHIM studies can make to Shigella vaccine development.<\/jats:p>","DOI":"10.1093\/cid\/ciz886","type":"journal-article","created":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T16:43:50Z","timestamp":1569689030000},"page":"S577-S579","source":"Crossref","is-referenced-by-count":9,"title":["Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview"],"prefix":"10.1093","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-0846","authenticated-orcid":false,"given":"Calman A","family":"MacLennan","sequence":"first","affiliation":[{"name":"Bill & Melinda Gates Foundation, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastazia Older","family":"Aguilar","sequence":"additional","affiliation":[{"name":"Bill & Melinda Gates Foundation, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Duncan","family":"Steele","sequence":"additional","affiliation":[{"name":"Bill & Melinda Gates Foundation, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"2019120911270943500_CIT0001","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2019120911270943500_CIT0002","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"2019120911270943500_CIT0003","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1017\/S0950268812001677","article-title":"The Shigella human challenge model","volume":"141","author":"Porter","year":"2013","journal-title":"Epidemiol Infect"},{"key":"2019120911270943500_CIT0004","doi-asserted-by":"crossref","first-page":"e01154","DOI":"10.1128\/AAC.01154-17","article-title":"Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody, in a human influenza A virus challenge model","volume":"61","author":"McBride","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2019120911270943500_CIT0005","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.1016\/j.vaccine.2017.10.093","article-title":"The frontline of controlled human malaria infections: a report from the controlled human infection models workshop in Leiden University Medical Centre 5 May 2016","volume":"35","author":"Roestenberg","year":"2017","journal-title":"Vaccine"},{"key":"2019120911270943500_CIT0006","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1093\/infdis\/jiv482","article-title":"Optimization of a human bacille Calmette-Gu\u00e9rin challenge model: a tool to evaluate antimycobacterial immunity","volume":"213","author":"Minhinnick","year":"2016","journal-title":"J Infect Dis"},{"key":"2019120911270943500_CIT0007","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14760584.2017.1291348","article-title":"PaxVax CVD 103-HgR single-dose live oral cholera vaccine","volume":"16","author":"Levine","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"2019120911270943500_CIT0008","first-page":"638","article-title":"Vaxchora: the first FDA-approved cholera vaccination in the United States","volume":"42","author":"Mosley","year":"2017","journal-title":"P T"},{"key":"2019120911270943500_CIT0009","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM200104263441701","article-title":"The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children","volume":"344","author":"Lin","year":"2001","journal-title":"New Engl J Med"},{"key":"2019120911270943500_CIT0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.vaccine.2018.04.022","article-title":"WHO report. Typhoid vaccines: WHO position paper, March 2018\u2014recommendations","volume":"37","author":"World Health Organization","year":"2019","journal-title":"Vaccine"},{"key":"2019120911270943500_CIT0011","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0140-6736(17)33296-8","article-title":"Shigellosis","volume":"391","author":"Kotloff","year":"2018","journal-title":"Lancet"},{"key":"2019120911270943500_CIT0012","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0140-6736(13)60844-2","article-title":"Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study","volume":"382","author":"Kotloff","year":"2013","journal-title":"Lancet"},{"key":"2019120911270943500_CIT0013","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/S0140-6736(16)31529-X","article-title":"Use of quantitative molecular diagnostic methods to identify causes of diarrhoea in children: a reanalysis of the GEMS case-control study","volume":"388","author":"Liu","year":"2016","journal-title":"Lancet"},{"key":"2019120911270943500_CIT0014","doi-asserted-by":"crossref","first-page":"e1319","DOI":"10.1016\/S2214-109X(18)30351-6","article-title":"Use of quantitative molecular diagnostic methods to investigate the effect of enteropathogen infections on linear growth in children in low-resource settings: longitudinal analysis of results from the MAL-ED cohort study","volume":"6","author":"Rogawski","year":"2018","journal-title":"Lancet Glob Health"},{"key":"2019120911270943500_CIT0015","author":"World Health Organization"},{"key":"2019120911270943500_CIT0016","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1001\/jama.1946.02870420002002","article-title":"Experimental human bacillary dysentery; polyvalent dysentery vaccine in its prevention","volume":"132","author":"Shaughnessy","year":"1946","journal-title":"J Am Med Assoc"},{"key":"2019120911270943500_CIT0017","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/infdis\/119.3.296","article-title":"The response of man to virulent Shigella flexneri 2a","volume":"119","author":"DuPont","year":"1969","journal-title":"J Infect Dis"},{"key":"2019120911270943500_CIT0018","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/infdis\/155.6.1260","article-title":"Prevention of shigellosis by a Salmonella Typhi\u2013Shigella sonnei bivalent vaccine","volume":"155","author":"Black","year":"1987","journal-title":"J Infect Dis"},{"key":"2019120911270943500_CIT0019","doi-asserted-by":"crossref","first-page":"7040","DOI":"10.1016\/j.vaccine.2012.09.061","article-title":"Establishment of a Shigella sonnei human challenge model in Thailand","volume":"30","author":"Bodhidatta","year":"2012","journal-title":"Vaccine"},{"key":"2019120911270943500_CIT0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/CVI.00665-15","article-title":"Clinical trial of an oral live Shigella sonnei vaccine candidate, WRSS1, in Thai adults","volume":"23","author":"Pitisuttithum","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"2019120911270943500_CIT0021","doi-asserted-by":"crossref","first-page":"6813","DOI":"10.1016\/j.vaccine.2017.05.068","article-title":"Developing and utilizing controlled human models of infection","volume":"35","author":"Porter","year":"2017","journal-title":"Vaccine"},{"key":"2019120911270943500_CIT0022","unstructured":"Talaat\n              KR\n            , AlaimoC, BourgeoisAL, et al\n          Flexyn2a, a candidate bioconjugate vaccine against Shigella flexneri 2a, induces protective immune response in a controlled human infection model. In: Final Oral and Poster Program of the Ninth Conference on Vaccines for Enteric Diseases,Albufeira, Portugal, 2017: 4."},{"key":"2019120911270943500_CIT0023","unstructured":"Frenck\n              RW\n            , DickeyM, SuvarnapunyaAE, et al\n          Development of a S. sonnei controlled human infection model using a lyophilized GMP lot of strain 53G. In: Final Oral and Poster Program of the Ninth Conference on Vaccines for Enteric Diseases,Albufeira, Portugal, 2017: 4."},{"key":"2019120911270943500_CIT0024","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1016\/j.vaccine.2016.02.075","article-title":"Status of vaccine research and development for Shigella","volume":"34","author":"Mani","year":"2016","journal-title":"Vaccine"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/Supplement_8\/S577\/31292334\/ciz886.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/Supplement_8\/S577\/31292334\/ciz886.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T11:27:19Z","timestamp":1575890839000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/Supplement_8\/S577\/5670763"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":24,"journal-issue":{"issue":"Supplement_8","published-online":{"date-parts":[[2019,12,9]]},"published-print":{"date-parts":[[2019,12,9]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz886","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12,15]]},"published":{"date-parts":[[2019,12,9]]}}}